

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the present application.

Listing of Claims:

1-6. (Canceled)

7. (Withdrawn - Currently Amended) A process for preparing a crystalline form of N-(3-cyano-4-methyl-1*H*-indol-7-yl)-3-cyanobenzenesulfonamide according to claim [[1,]] 23, comprising crystallizing N-(3-cyano-4-methyl-1*H*-indol-7-yl)-3-cyanobenzenesulfonamide using a simple solvent selected from the group consisting of n-propyl alcohol, isopropyl alcohol, n-butyl alcohol, s-butyl alcohol, t-butyl alcohol and water, or a mixed solvent thereof as a crystallization solvent.

8. (Withdrawn) A process according to claim 7, wherein the crystallization solvent is a simple solvent of isopropyl alcohol or s-butyl alcohol, or a mixed solvent of s-butyl alcohol and water or a mixed solvent of isopropyl alcohol and water.

9. (Withdrawn) A process according to claim 7, wherein the crystallization solvent is a mixed solvent of s-butyl alcohol and water (volume ratio = 3:1-5:1) or a mixed solvent of isopropyl alcohol and water (volume ratio = 9:1-10:1).

10. (Withdrawn) A process according to claim 7, wherein the crystallization solvent is a mixed solvent of s-butyl alcohol and water (volume ratio = 3.9:1-4.1:1).

11. **(Withdrawn)** A process according to claim 7, wherein N-(3-cyano-4-methyl-1*H*-indol-7-yl)-3-cyanobenzenesulfonamide is heated and dissolved in a solvent and then crystallized.

12. **(Withdrawn)** A process according to claim 7, wherein N-(3-cyano-4-methyl-1*H*-indol-7-yl)-3-cyanobenzenesulfonamide is heated and dissolved in a solvent and then crystallized by gradual cooling.

13. **(Withdrawn - Currently Amended)** A process for preparing a crystalline form of N-(3-cyano-4-methyl-1*H*-indol-7-yl)-3-cyanobenzenesulfonamide according to claim [1,] 23, wherein N-(3-cyano-4-methyl-1*H*-indol-7-yl)-3-cyanobenzenesulfonamide is heated at 80-130°C.

14. **(Withdrawn - Currently Amended)** A process for preparing a crystalline form of N-(3-cyano-4-methyl-1*H*-indol-7-yl)-3-cyanobenzenesulfonamide according to claim [1,] 23, wherein N-(3-cyano-4-methyl-1*H*-indol-7-yl)-3-cyanobenzenesulfonamide is heated and stirred in water at 60-90°C.

15. **(Withdrawn - Currently Amended)** A process for preparing a crystalline form of N-(3-cyano-4-methyl-1*H*-indol-7-yl)-3-cyanobenzenesulfonamide according to claim [1,] 23, wherein a crystalline form of N-(3-cyano-4-methyl-1*H*-indol-7-yl)-3-cyanobenzenesulfonamide hydrate is heated at 80-130°C.

16. **(Withdrawn - Currently Amended)** A process for preparing a crystalline form of N-(3-cyano-4-methyl-1*H*-indol-7-yl)-3-cyanobenzenesulfonamide according to claim [[1,]] 23, wherein a crystalline form of N-(3-cyano-4-methyl-1*H*-indol-7-yl)-3-cyanobenzenesulfonamide hydrate is heated and stirred in water at 60-90°C.

17- 22. **(Cancelled)**

23. **(Previously Presented)** A crystalline form of N-(3-cyano-4-methyl-1*H*-indol-7-yl)-3-cyanobenzenesulfonamide having the X-ray diffraction pattern substantially as depicted in Figure 3.

24-25. **(Canceled)**

26. **(Currently Amended)** A pharmaceutical composition comprising:
the crystalline form of N-(3-cyano-4-methyl-1*H*-indol-7-yl)-3-cyanobenzenesulfonamide according to claim [[1,]] 23 and
a pharmaceutically acceptable carrier.

27-28. **(Cancelled)**